Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Change in Receivables (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Change in Receivables for 12 consecutive years, with -$176000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Receivables fell 258.56% year-over-year to -$176000.0, compared with a TTM value of $558000.0 through Sep 2025, up 9.41%, and an annual FY2024 reading of $762000.0, up 514.13% over the prior year.
  • Change in Receivables was -$176000.0 for Q3 2025 at Arcadia Biosciences, down from $224000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $1.4 million in Q1 2022 and bottomed at -$1.1 million in Q4 2022.
  • Average Change in Receivables over 5 years is $14052.6, with a median of $65000.0 recorded in 2023.
  • The sharpest move saw Change in Receivables plummeted 15985.71% in 2022, then surged 1357.14% in 2024.
  • Year by year, Change in Receivables stood at -$7000.0 in 2021, then tumbled by 15985.71% to -$1.1 million in 2022, then surged by 105.77% to $65000.0 in 2023, then skyrocketed by 387.69% to $317000.0 in 2024, then plummeted by 155.52% to -$176000.0 in 2025.
  • Business Quant data shows Change in Receivables for RKDA at -$176000.0 in Q3 2025, $224000.0 in Q2 2025, and $193000.0 in Q1 2025.